Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a retrospective, observational review of anonymized US medical record data of patients diagnosed with IPSS low-risk () or intermediate-1-risk () MF. The majority of patients were male (low risk, 60%; intermediate-1 risk, 69%). Most patients (92% and 77%) were still receiving ruxolitinib at the medical record abstraction date (median observation/exposure time, 8 months). The proportion of patients with moderate or severe palpable splenomegaly (≥10 cm) decreased from diagnosis (56%) to best response (12%). Fatigue was reported in 47% of patients and was the most common constitutional symptom. For most symptoms in both risk groups, shifts in the distribution of severity from more to less severe from diagnosis to best response were observed. Both patients with low-risk and intermediate-1-risk MF experienced a substantial decrease in spleen size with ruxolitinib treatment in real-world settings. For most symptoms examined, there were distinct improvements in the distribution of severity during ruxolitinib treatment. These findings suggest that patients with lower-risk MF may benefit clinically from ruxolitinib treatment.
from #Medicine via ola Kala on Inoreader http://ift.tt/1lf1y8q
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
►
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
-
▼
2015
(2119)
- ► Δεκεμβρίου (940)
-
▼
Νοεμβρίου
(765)
-
▼
Νοε 09
(51)
- Medicine,New Articles,November 9th,2015
- Molecules, Vol. 20, Pages 20131-20145: Molecular D...
- Sensors, Vol. 15, Pages 28257-28270: The Mine Loco...
- Exacerbation of Dermatomyositis with Recurrence of...
- TRPM4 non-selective cation channels influence acti...
- Molecules, Vol. 20, Pages 20107-20117: Extremely R...
- IJMS, Vol. 16, Pages 26813-26831: Effect of Human ...
- IJMS, Vol. 16, Pages 26797-26812: The Function of ...
- IJMS, Vol. 16, Pages 26754-26769: Mobilization of ...
- IJMS, Vol. 16, Pages 26786-26796: Global Profiling...
- IJMS, Vol. 16, Pages 26770-26785: Numerical Analys...
- Molecules, Vol. 20, Pages 20118-20130: Design and ...
- Rapid bladder cancer cell detection from clinical ...
- Real-time imaging of cancer cell chemotaxis in pap...
- Amine neurotransmitters, inflammation and epitheli...
- IJERPH, Vol. 12, Pages 14244-14259: Factors Associ...
- IJERPH, Vol. 12, Pages 14216-14228: Physiological ...
- IJERPH, Vol. 12, Pages 14260-14274: Perceived Rele...
- IJERPH, Vol. 12, Pages 14229-14243: Variation in t...
- IJERPH, Vol. 12, Pages 14192-14215: Spatially Expl...
- IJERPH, Vol. 12, Pages 14275-14284: Associations b...
- Real-World Assessment of Clinical Outcomes in Pati...
- Acceptability of provider-initiated HIV testing as...
- Neonatal preintubation sedation: a national survey...
- Ambient temperature and prevalence of obesity: A n...
- Assessment of efficacy and safety of EUS-guided bi...
- Cirrhotic cardiomyopathy
- Epidemiology and healthcare resource utilization a...
- Gastric motor dysfunctions in Parkinson's disease:...
- Second-line treatment of metastatic gastric cancer...
- Trends in receipt and timing of multimodality ther...
- Features and progression of potential celiac disea...
- Vulnerability in elderly patients with gastrointes...
- Low risk of adenocarcinoma and high-grade dysplasi...
- Abdominal obesity and circulating metabolites: a t...
- Identification of patients at risk for colorectal ...
- Zinc intake and risk of Crohn’s disease and ulcera...
- Extensive modulation of the fecal metagenome in ch...
- Hepatitis C virus treatment as prevention in peopl...
- Hepatitis E infection in patients with severe alco...
- First report of an astrovirus type 5 gastroenterit...
- Clinical features of colorectal cancer patients in...
- Targeting host lipid synthesis and metabolism to i...
- Extracorporeal shock wave lithotripsy is a safe an...
- Selection of Single-Stranded DNA Molecular Recogni...
- Descemet’s Stripping Automated Endothelial Keratop...
- Dynamic Contrast-Enhanced CT Characterization of X...
- Effectiveness of workplace interventions in the pr...
- Transcriptome and Molecular Endocrinology Aspects ...
- Acute resistance exercise activates rapamycin-sens...
- Ascending aortic aneurysm caused by Mycobacterium ...
-
▼
Νοε 09
(51)
Αναζήτηση αυτού του ιστολογίου
Δευτέρα 9 Νοεμβρίου 2015
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.